GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alimera Sciences Inc (NAS:ALIM) » Definitions » Cash per Share

Alimera Sciences (Alimera Sciences) Cash per Share : $0.23 (As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Alimera Sciences Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Alimera Sciences's Cash per Share for the quarter that ended in Dec. 2023 was $0.23.

Alimera Sciences Cash per Share Historical Data

The historical data trend for Alimera Sciences's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alimera Sciences Cash per Share Chart

Alimera Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.90 1.96 2.38 0.75 0.23

Alimera Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.75 1.77 2.13 0.16 0.23

Alimera Sciences Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Alimera Sciences's Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=12.058/52.35
=0.23

Alimera Sciences's Cash per Share for the quarter that ended in Dec. 2023 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=12.058/52.35
=0.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alimera Sciences  (NAS:ALIM) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Alimera Sciences Cash per Share Related Terms

Thank you for viewing the detailed overview of Alimera Sciences's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Alimera Sciences (Alimera Sciences) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alimera Sciences Inc (NAS:ALIM) » Definitions » Cash per Share
Comparable Companies
ZOM LFCR TKNO OPTN ELTP RGC AQST EBS ESPR ETON ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 XSWX:SDZ VTRS NBIX
Traded in Other Exchanges
ASZ1:Germany
Address
6310 Town Square, Suite 400, Alpharetta, GA, USA, 30005
Website
https://www.alimerasciences.com
Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a leading cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East.
Executives
Margaret Pax director 6310 TOWN SQUARE, SUITE 400, ALPHARETTA GA 30005
John Snisarenko director C/O ALIMERA SCIENCES, INC., 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
Pizzo Peter J. Iii director 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
Erin Parsons director 97 WILLISTON RD, BROOKLINE MA 02445
Caligan Partners Lp 10 percent owner 515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022
Ross D Demont director 51 PICKWICK ROAD, NEWTON MA 02465
C. Daniel Myers other: Chairman Emeritus 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
David Edward Johnson 10 percent owner 590 MADISON AVENUE, NEW YORK NY 10022
Velan Capital Master Fund Lp 10 percent owner 1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Management Llc 10 percent owner 1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Holdings Llc 10 percent owner 1055B POWERS PLACE, ALPHARETTA GA 30009
Adam Morgan director 1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Investment Management Lp 10 percent owner 1055B POWERS PLACE, ALPHARETTA GA 30009
Velan Capital Spv I Llc 10 percent owner 1055B POWERS PLACE, ALPHARETTA GA 30009
Balaji Venkataraman 10 percent owner FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076